Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Temsirolimus in Metastatic Melanoma
NCT01851408Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Apr 2006
- Primary completion
- Feb 2012
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of temsirolimus, sorafenib in melanoma, sponsored by National Cancer Institute. Planned start Apr 2006; status: withdrawn.
02
Drugs
temsirolimussorafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01851408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01851408.